2 blue chip ASX 200 shares that could be strong buys

Ramsay Health Care Limited (ASX:RHC) and this blue chip ASX 200 share could be strong buys now. Here’s why they are highly rated by analysts…
The post 2 blue chip ASX 200 shares that could be strong buys appeared first on The Motley Fool Australia. –

A man with a yellow background makes an annoncement, indicating share price changes on the ASX

If you’re aiming to build a balanced portfolio, having a few blue chip ASX shares in there could be a smart move.

But which blue chip ASX 200 shares should you buy? Two that are highly rated are listed below:

CSL Limited (ASX: CSL)

The first blue chip ASX 200 share to look at is biotechnology giant CSL.

CSL has a focus on rare and serious diseases through its CSL Behring business and influenza vaccines through its Seqirus business.

CSL Behring has a wide range of innovative therapies. These are used to treat immunodeficiencies, bleeding disorders, hereditary angioedema, Alpha 1 antitrypsin deficiency, and neurological disorders. Whereas Seqirus has a broad range of flu products meeting the needs of different populations around the world.

While COVID-19 has impacted its plasma collections and could weigh on its margins in the near term, the long term looks extremely positive. Especially given its burgeoning R&D pipeline and the increasing demand for plasma-based products.

This morning, analysts at Credit Suisse upgraded CSL’s shares to an outperform rating with a $315.00 price target.

Ramsay Health Care Limited (ASX: RHC)

Another ASX 200 blue chip share to look at is Ramsay Health Care. It is a leading private healthcare company with operations across the world.

While the pandemic hit Ramsay hard and led to a significant drop in elective surgeries, trading conditions have improved greatly in recent months. As a result, Ramsay looks well-placed to benefit from a backlog in surgeries in the near term and increased demand for healthcare services over the long term. 

Macquarie is positive on the company. Earlier this week its analysts retained their outperform rating and $75.00 price target on Ramsay’s shares.

The broker has been pleased with recent activity trends and feels the company is well-positioned for growth over the long term.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 blue chip ASX 200 shares that could be strong buys appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!